Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?
Baer C, Huber S, Hutter S, Meggendorfer M, Nadarajah N, Walter W, Platzbecker U, Götze KS, Kern W, Haferlach T, Hoermann G, Haferlach C. Baer C, et al. Among authors: platzbecker u. Leukemia. 2023 Apr;37(4):938-941. doi: 10.1038/s41375-023-01831-1. Epub 2023 Feb 1. Leukemia. 2023. PMID: 36725896 Free PMC article. No abstract available.
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A. Germing U, et al. Among authors: platzbecker u. Leukemia. 2012 Jun;26(6):1286-92. doi: 10.1038/leu.2011.391. Epub 2012 Jan 13. Leukemia. 2012. PMID: 22289990
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M. Platzbecker U, et al. Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. Leukemia. 2013. PMID: 23354011 Free PMC article. Clinical Trial. No abstract available.
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Braulke F, et al. Among authors: platzbecker u. Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25. Leuk Res. 2013. PMID: 23623559 Clinical Trial.
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A. Platzbecker U, et al. Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. Leukemia. 2014. PMID: 24186004 Clinical Trial. No abstract available.
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U. Neukirchen J, et al. Among authors: platzbecker u. Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26. Leuk Res. 2014. PMID: 24238640
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K. Müller-Thomas C, et al. Among authors: platzbecker u. Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. Haematologica. 2014. PMID: 24972774 Free PMC article. No abstract available.
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Heuser M, et al. Among authors: platzbecker u. Leukemia. 2015 Sep;29(9):1942-5. doi: 10.1038/leu.2015.49. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25792355 No abstract available.
602 results